相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Synergistic Cytotoxic and Apoptotic Effects of Local Probiotic Lactobacillus Brevis Isolated from Regional Dairy Products in Combination with Tamoxifen
Zahra Nasiri et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2021)
Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer
Youssef El-Ahmad et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting selective autophagy by AUTAC degraders
Daiki Takahashi et al.
AUTOPHAGY (2020)
Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α
Yuxuan Dai et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
PHOTACs enable optical control of protein degradation
Martin Reynders et al.
SCIENCE ADVANCES (2020)
Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
Xin Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance
Mingjun Bi et al.
NATURE CELL BIOLOGY (2020)
Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance
Xin Lin et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer
Siyu Ma et al.
CANCER (2020)
Computer-Aided Ligand Discovery for Estrogen Receptor Alpha
Divya Bafna et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer
Annamaria Salvati et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)
Yuanyuan Li et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
A chemical approach for global protein knockdown from mice to non-human primates
Xiuyun Sun et al.
CELL DISCOVERY (2019)
Selective oestrogen receptor degraders in breast cancer: a review and perspectives
Andrea Gombos
CURRENT OPINION IN ONCOLOGY (2019)
A glycine-specific N-degron pathway mediates the quality control of protein N-myristoylation
Richard T. Timms et al.
SCIENCE (2019)
Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders
Jiuling Yang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
PROTAC-Mediated Degradation of Estrogen Receptor in the Treatment of Cancer
Robert B. Kargbo
ACS Medicinal Chemistry Letters (2019)
A modular PROTAC design for target destruction using a degradation signal based on a single amino acid
Karthigayan Shanmugasundaram et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
The PROTAC technology in drug development
Yutian Zou et al.
CELL BIOCHEMISTRY AND FUNCTION (2019)
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Kamal Pandey et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)
Jiantao Hu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer
Yunlong Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927
Mehmet Kahraman et al.
ACS MEDICINAL CHEMISTRY LETTERS (2019)
Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER
Rainer Girgert et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers
Suryavathi Viswanadhapalli et al.
BREAST CANCER RESEARCH (2019)
Bivalent Ligands for Protein Degradation in Drug Discovery
Marcel Scheepstra et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer
J. J. Flanagan et al.
CANCER RESEARCH (2019)
PROTACs: great opportunities for academia and industry
Xiuyun Sun et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer
Sean W. Fanning et al.
ENDOCRINOLOGY (2019)
Duality of estrogen receptor β action in cancer progression
T. C. Guillette et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor
Zunyuan Wang et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2018)
New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons
Lucia Wang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2018)
Homo-PROTACs for the Chemical Knockdown of Cereblon
Christian Steinebach et al.
ACS CHEMICAL BIOLOGY (2018)
Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
Sainan An et al.
EBIOMEDICINE (2018)
Development of Stabilized Peptide-Based PROTACs against Estrogen Receptor alpha
Yanhong Jiang et al.
ACS CHEMICAL BIOLOGY (2018)
Cornerstones of CRISPR-Cas in drug discovery and therapy
Christof Fellmann et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)
Nobumichi Ohoka et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Design and synthesis of novel selective estrogen receptor degradation inducers based on the diphenylheptane skeleton
Takashi Misawa et al.
MEDCHEMCOMM (2017)
Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers
Ganesh V. Raj et al.
ELIFE (2017)
Fulvestrant in advanced breast cancer: evidence to date and place in therapy
Katalin Boer
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors
Yuechao Zhao et al.
CANCER RESEARCH (2017)
Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models
Teeru Bihani et al.
CLINICAL CANCER RESEARCH (2017)
Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy
Philipp Ottis et al.
ACS CHEMICAL BIOLOGY (2017)
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models
Hazel M. Weir et al.
CANCER RESEARCH (2016)
Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras
Honorine Lebraud et al.
ACS CENTRAL SCIENCE (2016)
Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging
Jeffrey L. Gustafson et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Estrogen receptor alpha and beta in health and disease
Min Jia et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts
Andiliy Lai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Knocking down disease: a progress report on siRNA therapeutics
Anders Wittrup et al.
NATURE REVIEWS GENETICS (2015)
Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator
Takuji Shoda et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells
Keiichiro Okuhira et al.
CANCER SCIENCE (2013)
Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy
Yosuke Demizu et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides
Manghong Zhu et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2012)
Design, synthesis and biological evaluation of nuclear receptor-degradation inducers
Yukihiro Itoh et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Discovering Small-Molecule Estrogen Receptor α/Coactivator Binding Inhibitors: High-Throughput Screening, Ligand Development, and Models for Enhanced Potency
Aiming Sun et al.
CHEMMEDCHEM (2011)
Impact of linker length on the activity of PROTACs
Kedra Cyrus et al.
MOLECULAR BIOSYSTEMS (2011)
Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins
Taavi K. Neklesa et al.
NATURE CHEMICAL BIOLOGY (2011)
The different roles of ER subtypes in cancer biology and therapy
Christoforos Thomas et al.
NATURE REVIEWS CANCER (2011)
Two-Headed PROTAC: An Effective New Tool for Targeted Protein Degradation
Kedra Cyrus et al.
CHEMBIOCHEM (2010)
Jostling for Position: Optimizing Linker Location in the Design of Estrogen Receptor-Targeting PROTACs
Kedra Cyrus et al.
CHEMMEDCHEM (2010)
Protein Knockdown Using Methyl Bestatin-Ligand Hybrid Molecules: Design and Synthesis of Inducers of Ubiquitination-Mediated Degradation of Cellular Retinoic Acid-Binding Proteins
Yukihiro Itoh et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
Unliganded estrogen receptor-β regulation of genes is inhibited by tamoxifen
Nitzan Levy et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2010)
Mechanisms of estrogen receptor-α upregulation in breast cancers
Yasuo Miyoshi et al.
MEDICAL MOLECULAR MORPHOLOGY (2010)
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
Ashley R. Schneekloth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Coregulators in nuclear estrogen receptor action - From concept to therapeutic targeting
JM Hall et al.
MOLECULAR INTERVENTIONS (2005)
Use of PROTACS as molecular probes of angiogenesis
P Bargagna-Mohan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
Chemical genetic control of protein levels: Selective in vivo targeted degradation
JS Schneekloth et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action
CK Osborne et al.
BRITISH JOURNAL OF CANCER (2004)
Degradation of target protein in living cells by small-molecule proteolysis inducer
D Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2004)
Bridged bicyclic cores containing a 1,1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor
RS Muthyala et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Development of protacs to target cancer-promoting proteins for ubiquitination and degradation
KM Sakamoto et al.
MOLECULAR & CELLULAR PROTEOMICS (2003)
Protacs: Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation
KM Sakamoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
